Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Institut Gustave Roussy
Sponsor

Institut Gustave Roussy

France 114 Rue Edouard Vaillant, 94800 Villejuif, France

About the sponsor

Research activity includes non-small cell lung cancer, small-cell lung cancer, and other poorly differentiated neuroendocrine carcinomas, with additional interest in pancreatic ductal adenocarcinoma, oligometastatic disease, and biomarker-defined tumour subsets.

  • NSCLC
  • SCLC and neuroendocrine carcinomas
  • Pancreatic cancer
  • Oligometastatic solid tumours

Work in this area also extends to metastatic renal cell carcinoma and KRAS G12C-mutated lung cancer, reflecting a strong focus on targeted and immunologic treatment strategies.

About Specializations

Institut Gustave Roussy runs clinical trials in conditions such as Non-small cell lung cancer, Neoplasm, Breast cancer, Rectal adenocarcinoma, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

40 clinical trials

Osteosarcoma

Recruiting

Cabozantinib Maintenance Therapy vs Best Supportive Care in Osteosarcoma Patients in Complete Remission or with Residual Disease after First‑Line Chemotherapy

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Rectal adenocarcinoma

Recruiting

Phase II Study of Intratumoral Hydrogen Peroxide (KRC-01) Combined with Radiotherapy for Locally Advanced Rectal Cancer

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Hydrogen peroxide
  • Sponsor:Institut Gustave Roussy

Neoplasm

Recruiting

A Study of Valemetostat Tosylate in Adult Patients with Advanced Solid Tumors That Have Specific Gene Changes or Are Clear Cell Endometrial or Ovarian Cancers

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Valemetostat Tosilate
  • Sponsor:Institut Gustave Roussy

Adenocarcinoma pancreas+1

Recruiting

A study testing ASP3082 in patients with advanced or spreading non-small cell lung cancer and pancreatic ductal adenocarcinoma

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:ASP3082
  • Sponsor:Institut Gustave Roussy

Acute myeloid leukaemia

Recruiting

A Study Comparing Two Treatment Schedules of Venetoclax and Azacitidine in Adults with Newly Diagnosed Acute Myeloid Leukemia Not Suitable for Intensive Treatment

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Azacitidine
  • Sponsor:Institut Gustave Roussy

Breast cancer

Recruiting

Evaluating elacestrant alone or with leuprorelin in premenopausal women with early-stage hormone receptor positive breast cancer before surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Leuprorelin Acetate
  • Sponsor:Institut Gustave Roussy

Small cell lung cancer metastatic+1

Recruiting

Study of Tarlatamab for Patients with Metastatic or Advanced Small-Cell Lung Cancer and Neuroendocrine Carcinomas

InvestigationalNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tarlatamab
  • Sponsor:Institut Gustave Roussy

Non-small cell lung cancer

Recruiting

Study on MaaT033 and Cemiplimab for Patients with Advanced Non-Small Cell Lung Cancer Resistant to PD-1/PD-L1 Blockade Due to Antibiotic Use

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Institut Gustave Roussy

Clear cell renal cell carcinoma

Recruiting

Study on Cabozantinib and Nivolumab for Older Patients with Kidney Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:65+ years
  • Substances:Cabozantinib
  • Sponsor:Institut Gustave Roussy

Non-small cell lung cancer

Recruiting

Study on the Effectiveness of Cemiplimab and Drug Combination for Patients with Oligometastatic Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Institut Gustave Roussy

Neuroblastoma

Recruiting

Study on High-Risk Neuroblastoma Treatment with Busulfan, Melphalan, and Drug Combination for Patients with Insufficient Metastatic Response

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Busulfan
  • Sponsor:Institut Gustave Roussy

Neoplasm

Recruiting

Study on the Safety and Efficacy of Tretinoin with Radiation Therapy for Patients with Oligometastatic Solid Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Tretinoin
  • Sponsor:Institut Gustave Roussy

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.